{"database":"ENA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["Zhejiang Shaoxing Topgen Biomedical Technology Co., LTD."],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA1077640"],"long_description":["Next generation sequencing (NGS) was performed on the tumor DNA of a lung adenocarcinoma patient, revealing a fusion between VIT exon 2 and ALK exon 20 with a variant frequency of 10.32%. After one year of therapy, the patient remained in a stable disease state. However, the patient experienced a relapse and underwent a second NGS test. The results showed a fusion of exon 2 of VIT with exon 20 of ALK, with a variant frequency of 13.13%. Ultimately, the patient achieved a progression free survival of 16 months."],"repository":["ENA"],"description_synonyms":["non-small cell lung cancer, non-small cell cancer of the lung, non-small cell carcinoma of lung, NSCLC, Client., Patient, non-small cell lung carcinoma, Clients, NSCLC - non-small cell lung cancer, patient, Non-small cell lung cancer, non-small cell cancer of lung, non-small cell carcinoma of the lung, non-small cell lung carcinoma (disease)"],"additional_accession":[]},"is_claimable":false,"name":"","description":"Next generation sequecing data of a NSCLC patient","dates":{"last_updated":"2024-05-11","first_public":"2024-05-11"},"accession":"PRJNA1077640","cross_references":{}}